Loading...

We've got a brand new version of Simply Wall St! Try it out

glac Biotech

GTSM:6553
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6553
GTSM
NT$3B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

glac Biotech Co., Ltd. develops, manufactures, and markets probiotic in Taiwan and internationally. The last earnings update was 89 days ago. More info.


Add to Portfolio Compare Print
6553 Share Price and Events
7 Day Returns
0%
GTSM:6553
-1%
TW Biotechs
1.4%
TW Market
1 Year Returns
42.8%
GTSM:6553
-9.6%
TW Biotechs
17.7%
TW Market
6553 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
glac Biotech (6553) 0% 0% -0.5% 42.8% 17.1% -
TW Biotechs -1% -2.6% -4.5% -9.6% -39.9% -41.4%
TW Market 1.4% 6% 9.8% 17.7% 27.6% 27.7%
1 Year Return vs Industry and Market
  • 6553 outperformed the Biotechs industry which returned -9.6% over the past year.
  • 6553 outperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
6553
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for glac Biotech's competitors could be found in our database.

6553 Value

 Is glac Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of glac Biotech to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for glac Biotech.

GTSM:6553 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-06-30) in TWD NT$ 3.000000
Payout Ratio Company Filings (2019-06-30) 22717.7%
Discount Rate (Cost of Equity) See below 11%
Perpetual Growth Rate 10-Year TW Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for GTSM:6553
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.28
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.278 (1 + (1- 20%) (1.14%))
1.392
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.39
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.392 * 5.96%)
11.03%

Discounted Cash Flow Calculation for GTSM:6553 using Dividend Discount Model Model

The calculations below outline how an intrinsic value for glac Biotech is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

GTSM:6553 Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= NT$3 / (11.03% - 2.73%)
NT$16.37
GTSM:6553 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$16.37
Current discount Discount to share price of NT$44.28
= -1 x (NT$44.28 - NT$16.37) / NT$16.37
-170.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of glac Biotech is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for glac Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are glac Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:6553 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in TWD NT$0.37
GTSM:6553 Share Price ** GTSM (2019-11-08) in TWD NT$44.28
Taiwan, Province of China Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 41.22x
Taiwan, Province of China Market PE Ratio Median Figure of 1,438 Publicly-Listed Companies 16.62x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of glac Biotech.

GTSM:6553 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:6553 Share Price ÷ EPS (both in TWD)

= 44.28 ÷ 0.37

121.17x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • glac Biotech is overvalued based on earnings compared to the TW Biotechs industry average.
  • glac Biotech is overvalued based on earnings compared to the Taiwan, Province of China market.
Price based on expected Growth
Does glac Biotech's expected growth come at a high price?
Raw Data
GTSM:6553 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 121.17x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
15.2%per year
Asia Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.61x
Taiwan, Province of China Market PEG Ratio Median Figure of 244 Publicly-Listed Companies 1.14x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for glac Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on glac Biotech's assets?
Raw Data
GTSM:6553 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in TWD NT$15.13
GTSM:6553 Share Price * GTSM (2019-11-08) in TWD NT$44.28
Taiwan, Province of China Biotechs Industry PB Ratio Median Figure of 40 Publicly-Listed Biotechs Companies 3.4x
Taiwan, Province of China Market PB Ratio Median Figure of 1,939 Publicly-Listed Companies 1.46x
GTSM:6553 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:6553 Share Price ÷ Book Value per Share (both in TWD)

= 44.28 ÷ 15.13

2.93x

* Primary Listing of glac Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • glac Biotech is good value based on assets compared to the TW Biotechs industry average.
X
Value checks
We assess glac Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. glac Biotech has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

6553 Future Performance

 How is glac Biotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover glac Biotech, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
15.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is glac Biotech expected to grow at an attractive rate?
  • glac Biotech's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • glac Biotech's earnings growth is expected to exceed the Taiwan, Province of China market average.
  • Unable to compare glac Biotech's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:6553 Future Growth Rates Data Sources
Data Point Source Value (per year)
GTSM:6553 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 15.2%
Taiwan, Province of China Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 65.2%
Taiwan, Province of China Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 60.6%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.3%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 7.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:6553 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:6553 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-06-30 836 56 26
2019-03-31 912 86 61
2018-12-31 989 116 95
2018-09-30 973 125 94
2018-06-30 956 133 93
2018-03-31 910 171 71
2017-12-31 797 175 51
2017-09-30 746 138 33
2017-06-30 696 101 15
2017-03-31 623 87 16
2016-12-31 667 70 1
2016-09-30 628 68 15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • glac Biotech's earnings are expected to grow by 15.2% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if glac Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:6553 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from glac Biotech Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6553 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-06-30 0.37
2019-03-31 0.84
2018-12-31 1.32
2018-09-30 1.31
2018-06-30 1.29
2018-03-31 0.96
2017-12-31 0.71
2017-09-30 0.45
2017-06-30 0.20
2017-03-31 0.27
2016-12-31 0.02
2016-09-30 0.26

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if glac Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess glac Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
glac Biotech has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

6553 Past Performance

  How has glac Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare glac Biotech's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • glac Biotech has delivered over 20% year on year earnings growth in the past 5 years.
  • glac Biotech's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • glac Biotech's 1-year earnings growth is negative, it can't be compared to the TW Biotechs industry average.
Earnings and Revenue History
glac Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from glac Biotech Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6553 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 836.08 26.37 193.35 85.64
2019-03-31 912.50 60.84 195.79 79.82
2018-12-31 988.91 95.31 198.23 73.99
2018-09-30 972.55 94.21 195.87 64.47
2018-06-30 956.18 93.11 193.51 54.94
2018-03-31 910.10 71.24 184.63 56.65
2017-12-31 797.08 51.18 159.88 49.74
2017-09-30 746.32 33.28 146.97 52.39
2017-06-30 695.57 15.38 134.06 55.04
2017-03-31 622.71 15.71 144.32 39.21
2016-12-31 666.51 1.46 156.75 51.51
2016-09-30 627.65 14.68 152.66 40.81
2016-06-30 588.78 27.91 148.57 30.10
2016-03-31 516.70 41.85 110.56 21.41
2015-12-31 472.01 43.95 102.78 16.45
2015-09-30 388.85 34.77 89.05 13.43
2015-06-30 305.69 25.59 75.33 10.40
2015-03-31 244.53 16.66 65.14 10.24
2014-12-31 183.38 7.73 54.95 10.08
2013-12-31 78.62 -17.84 34.66 6.09
2012-12-31 40.60 -18.23 26.26 6.52

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • glac Biotech has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • glac Biotech used its assets less efficiently than the TW Biotechs industry average last year based on Return on Assets.
  • glac Biotech's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess glac Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
glac Biotech has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

6553 Health

 How is glac Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up glac Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • glac Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • glac Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of glac Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 62.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from glac Biotech Company Filings, last reported 4 months ago.

GTSM:6553 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 1,250.94 10.00 353.74
2019-03-31 1,250.94 10.00 353.74
2018-12-31 1,353.87 0.00 517.78
2018-09-30 1,353.87 0.00 517.78
2018-06-30 1,322.94 0.00 521.93
2018-03-31 1,322.94 0.00 521.93
2017-12-31 1,463.13 10.00 794.30
2017-09-30 1,463.13 10.00 794.30
2017-06-30 1,273.53 0.00 733.60
2017-03-31 1,244.10 50.05 635.85
2016-12-31 1,387.61 96.75 692.85
2016-09-30 1,387.61 96.75 692.85
2016-06-30 743.77 96.83 166.61
2016-03-31 732.06 18.73 256.79
2015-12-31 732.06 18.73 256.79
2015-09-30 732.06 18.73 256.79
2015-06-30 692.72 0.00 337.16
2015-03-31 692.72 0.00 337.16
2014-12-31 540.20 19.10 306.56
2013-12-31 123.02 5.00 11.52
2012-12-31 130.80 0.00 48.25
  • glac Biotech's level of debt (0.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (3.6% vs 0.8% today).
  • Debt is well covered by operating cash flow (565%, greater than 20% of total debt).
  • glac Biotech earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess glac Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. glac Biotech has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

6553 Dividends

 What is glac Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
6.78%
Current annual income from glac Biotech dividends.
If you bought NT$2,000 of glac Biotech shares you are expected to receive NT$136 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • glac Biotech's pays a higher dividend yield than the bottom 25% of dividend payers in Taiwan, Province of China (2.59%).
  • glac Biotech's dividend is above the markets top 25% of dividend payers in Taiwan, Province of China (5.95%).
Upcoming dividend payment

Purchase glac Biotech before the 'Ex-dividend' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:6553 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1337 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:6553 Past Annualized Dividends Data
Date (Data in NT$) Dividend per share (annual) Avg. Yield (%)
2018-08-14 3.000 7.775
2018-03-29 3.000 7.426
2018-03-27 3.000 7.328

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, glac Biotech has been paying a dividend for less than 10 years.
  • glac Biotech has only been paying a dividend for 2 years, and since then there has been no growth.
Current Payout to shareholders
What portion of glac Biotech's earnings are paid to the shareholders as a dividend.
  • Dividends paid are not well covered by earnings (0.1x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess glac Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can glac Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. glac Biotech has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

6553 Management

 What is the CEO of glac Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Zhong Wei Guo
CEO Bio

Zhong Wei Guo serves as the Chairman and President at glac Biotech Co., Ltd. Zhong Wei Guo served as the President of ProMD Biotech Co., Ltd. Zhong Wei Guo served as Manager of Intellectual Property Department of Pricewaterhouse Coopers Legal. Zhong Wei Guo served as Manager of Law Department of Shining Construction Company. Zhong Wei Guo served as Manager of Legal Affairs of GenMont Biotech Inc. Zhong Wei Guo serves as the Chairman of the Board of Directors Jinqiao Biological Technology Co., Ltd. (Huai'an), Anhui Jinlac Biotech Ltd., Jinqi Biotechnology (Anhui) Co., Ltd., GLAC&GEORGE Biotech Co., Ltd. (HK) and JLC Biotech Holding Limited. Zhong Wei Guo studied from Graduate School of Neuroscience at Yanming University and Graduate School of Law, National Chengchi University. Zhong Wei Guo holds Bachelor's Degree in Agriculture Chemistry from National Taiwan University and Bachelor's Degree in Law from Soochow University.

CEO Compensation
  • Insufficient data for Zhong Wei to compare compensation growth.
  • Insufficient data for Zhong Wei to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team

Zhong Wei Guo

TITLE
Chairman and President
Board of Directors

Zhong Wei Guo

TITLE
Chairman and President

Yong Chang Cheng

TITLE
Independent Director

Wan Zheng

TITLE
Director

Su Qi Wang

TITLE
Director

Zhong Liang Li

TITLE
Director

Qi Xing Zhang

TITLE
Independent Director

Zhong Chuan Shi

TITLE
Independent Director

Guo Yan

TITLE
Member of the Supervisory Board

Li Ye Zhang

TITLE
Member of the Supervisory Board

Shang E Zeng

TITLE
Member of the Supervisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess glac Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. glac Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

6553 News

Simply Wall St News

6553 Company Info

Description

glac Biotech Co., Ltd. develops, manufactures, and markets probiotic in Taiwan and internationally. It offers Probiotic raw materials; and postbiotics, heat-killed lactobacillus salivarius, heat-killed lactobacillus paracasei, and fermented liquid. The company also provides health supplements, such as G-Pro Probiotic that help curb gas, bloating, and upset stomach, and works to boost immune system; V-Pro Probiotics for gut to vaginal health; S-Pro Probiotic for antagonizing helicobacter pylori in the stomach; and A-Pro Probiotic to boost immune system. In addition, it offers food products comprising ICEYO, a sterilized yogurt concentrate for making yogurt ice cream; and peptide corn soup. Further, the company provides beauty products consisting of FDORA lacto face mask, as well as engages in the contract manufacturing of probiotic applications. glac Biotech Co., Ltd. was founded in 2008 and is headquartered in Tainan, Taiwan.

Details
Name: glac Biotech Co., Ltd.
6553
Exchange: GTSM
Founded: 2008
NT$3,195,731,880
72,171,000
Website: http://www.glac.com.tw
Address: glac Biotech Co., Ltd.
No. 17, Guoji Road,
4th Floor,
Tainan,
74442,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 6553 Share Capital Taipei Exchange TW TWD 30. Oct 2015
Number of employees
Current staff
Staff numbers
0
glac Biotech employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/11 15:06
End of day share price update: 2019/11/08 00:00
Last earnings filing: 2019/08/14
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.